Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study - Matteo Santoni; Zin Myint; Thomas Büttner; Hideki Takeshita; Y. Okada; Elaine T. Lam; Danielle Gilbert; Zsófia Kürönya; Deniz Tural; Renate Pichler; Enrique Grande; Simon J. Crabb; et al. (2023)